Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.62
(0.0%)
USD 0.62
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.47 Billion CNY | 13.84% |
| 2022 | 1.29 Billion CNY | 58.25% |
| 2021 | 819.22 Million CNY | 41.7% |
| 2020 | 578.12 Million CNY | -54.95% |
| 2019 | 1.28 Billion CNY | 40.81% |
| 2018 | 911.33 Million CNY | -0.45% |
| 2017 | 915.48 Million CNY | -0.23% |
| 2016 | 917.54 Million CNY | 195123.19% |
| 2015 | 470 Thousand CNY | 0.0% |
| 2014 | - CNY | -100.0% |
| 2013 | 39.31 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | 0.0% |
| 2007 | - CNY | 100.0% |
| 2006 | -11.23 Million CNY | 10.46% |
| 2005 | -12.54 Million CNY | 0.0% |
| 2004 | - CNY | 0.0% |
| 2003 | - CNY | 0.0% |
| 2002 | - CNY | 0.0% |
| 2001 | - CNY | 0.0% |
| 2000 | - CNY | 0.0% |
| 1999 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.73 Billion CNY | 17.83% |
| 2024 Q2 | 1.73 Billion CNY | 0.0% |
| 2023 Q2 | 1.5 Billion CNY | 0.0% |
| 2023 FY | 1.47 Billion CNY | 13.84% |
| 2023 Q1 | 1.5 Billion CNY | 16.23% |
| 2023 Q4 | 1.47 Billion CNY | 0.0% |
| 2023 Q3 | 1.47 Billion CNY | -2.06% |
| 2022 Q1 | 1 Billion CNY | 22.16% |
| 2022 Q2 | 1 Billion CNY | 0.0% |
| 2022 Q3 | 1.29 Billion CNY | 29.54% |
| 2022 Q4 | 1.29 Billion CNY | 0.0% |
| 2022 FY | 1.29 Billion CNY | 58.25% |
| 2021 Q2 | 838.46 Million CNY | 0.0% |
| 2021 Q4 | 819.22 Million CNY | 0.0% |
| 2021 Q1 | 838.45 Million CNY | 45.03% |
| 2021 FY | 819.22 Million CNY | 41.7% |
| 2021 Q3 | 819.22 Million CNY | -2.29% |
| 2020 FY | 578.12 Million CNY | -54.95% |
| 2020 Q1 | 1.27 Billion CNY | -0.88% |
| 2020 Q2 | 1.27 Billion CNY | 0.0% |
| 2020 Q3 | 578.12 Million CNY | -54.55% |
| 2020 Q4 | 578.12 Million CNY | 0.0% |
| 2019 Q3 | 1.28 Billion CNY | 31.28% |
| 2019 Q1 | 977.47 Million CNY | 7.26% |
| 2019 Q2 | 977.47 Million CNY | 0.0% |
| 2019 Q4 | 1.28 Billion CNY | 0.0% |
| 2019 FY | 1.28 Billion CNY | 40.81% |
| 2018 Q1 | 913.64 Million CNY | -0.2% |
| 2018 Q4 | 911.33 Million CNY | 0.0% |
| 2018 FY | 911.33 Million CNY | -0.45% |
| 2018 Q2 | 913.64 Million CNY | 0.0% |
| 2018 Q3 | 911.33 Million CNY | -0.25% |
| 2017 Q2 | 917.78 Million CNY | 0.0% |
| 2017 Q4 | 915.48 Million CNY | 0.0% |
| 2017 FY | 915.48 Million CNY | -0.23% |
| 2017 Q3 | 915.48 Million CNY | -0.25% |
| 2017 Q1 | 917.78 Million CNY | 0.03% |
| 2016 Q1 | 492 Thousand CNY | 4.68% |
| 2016 Q2 | 492 Thousand CNY | 0.0% |
| 2016 Q3 | 917.54 Million CNY | 186393.7% |
| 2016 Q4 | 917.54 Million CNY | 0.0% |
| 2016 FY | 917.54 Million CNY | 195123.19% |
| 2015 FY | 470 Thousand CNY | 0.0% |
| 2015 Q1 | 3.4 Million CNY | 0.0% |
| 2015 Q2 | 3.4 Million CNY | 0.0% |
| 2015 Q3 | 470 Thousand CNY | -86.2% |
| 2015 Q4 | 470 Thousand CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2014 FY | - CNY | -100.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2013 Q4 | 39.31 Million CNY | 0.0% |
| 2013 FY | 39.31 Million CNY | 0.0% |
| 2013 Q3 | 39.31 Million CNY | -1.31% |
| 2013 Q2 | 39.83 Million CNY | 0.0% |
| 2013 Q1 | 39.83 Million CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2009 Q4 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2008 FY | - CNY | 0.0% |
| 2007 FY | - CNY | 100.0% |
| 2006 FY | -11.23 Million CNY | 10.46% |
| 2005 FY | -12.54 Million CNY | 0.0% |
| 2004 FY | - CNY | 0.0% |
| 2003 FY | - CNY | 0.0% |
| 2002 FY | - CNY | 0.0% |
| 2001 FY | - CNY | 0.0% |
| 2000 FY | - CNY | 0.0% |
| 1999 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 93.392% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 96.135% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -1278.593% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 92.633% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -7510.88% |